Targets › EGFR
185 programs from 133 companies in 528 trials: 245 Phase 2, 192 Phase 1, 82 Phase 3, 9 Phase 4; Oncology, Other, Immunology; next expected readout Nov 2026.
Receptor tyrosine kinase binding ligands of the EGF family and activating several signaling cascades to convert extracellular cues into appropriate cellular responses. Known ligands include EGF, TGFA/TGF-alpha, AREG, epigen/EPGN, BTC/betacellulin, epiregulin/EREG and HBEGF/heparin-binding EGF. Ligand binding triggers receptor homo- and/or heterodimerization and autophosphorylation on key cytoplasmic residues. (UniProt, P00533)
Open in Phaseline: the race on EGFR, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| AstraZeneca | Osimertinib Epidermal growth factor receptor erbB1 inhibitor | EGFR | Phase 4 | Non-small Cell Lung Cancer; Carcinoma; Metastatic Non-small Cell Lung Cancer; Cancer … | Nov 2026 |
| Michael Hopp | Afatinib Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor | EGFR, ERBB2, ERBB4 | Phase 4 | Non-squamous NSCLC | Dec 2026 |
| Fudan University | Befotertinib Third-generation selective EGFR tyrosine-kinase inhibitor | EGFR | Phase 4 | 3-year Disease-free Survival | May 2027 |
| Psoriasis Treatment Center of Central New Jersey | Duobrii Dual EGFR and ErbB2 inhibitor topical cream | EGFR, ERBB2 | Phase 4 | Psoriasis | – |
| Sichuan Baili Pharmaceutical | SI-B001 EGFR/HER3 bispecific antibody | EGFR, HER3 | Phase 3 | Non-small Cell Lung Adenocarcinoma; Non-small Cell Lung Cancer; Esophageal Squamous Cell Carcinomas; Head and Neck Squamous Cell Carcinoma … | Nov 2026 |
| Shanghai JMT-Bio | JMT101 Anti-EGFR monoclonal antibody | EGFR | Phase 3 | Locally Advanced or Metastatic Non-squamous NSCLC; Local Advanced or Metastatic NSCLC | Nov 2026 |
| Shanghai JMT-Bio | Osimertinib mesylate Epidermal growth factor receptor erbB1 inhibitor | EGFR | Phase 3 | Non-Small Cell Lung Cancer; Local Advanced or Metastatic NSCLC | Nov 2026 |
| Jiangsu Aosaikang Pharmaceutical | ASKC202 EGFR tyrosine kinase inhibitor | EGFR | Phase 3 | Locally Advanced or Metastatic NSCLC; Advanced Solid Tumor | Dec 2026 |
| Allist Pharmaceuticals | Firmonertinib Epidermal growth factor receptor erbB1 inhibitor | EGFR | Phase 3 | Non-small Cell Lung Carcinoma; EGFR; NSCLC; Leptomeningeal Metastasis … | Dec 2026 |
| Sun Yat-sen University | Nimotuzumab Epidermal growth factor receptor erbB1 inhibitor | EGFR | Phase 3 | Nasopharyngeal Carcinoma; Nasopharyngeal Carcinoma (NPC) | Dec 2026 |
| Jiangsu HengRui Medicine | Pyrotinib Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor | EGFR, ERBB2 | Phase 3 | Breast Cancer; Advanced Non-small Cell Lung Cancer; HER2-positive Breast Cancer; Metastatic Breast Cancer … | Dec 2026 |
| Dizal Pharmaceuticals | Sunvozertinib EGFR Exon20ins inhibitor | EGFR | Phase 3 | Non-small Cell Lung Cancer; Non-Small Cell Lung Cancer; NSCLC; Non Small Cell Lung Cancer … | Dec 2026 |
| Johnson & Johnson (Janssen) | Amivantamab Epidermal growth factor receptor erbB1 inhibitor; Hepatocyte growth factor receptor inhibitor | EGFR, MET | Phase 3 | Advanced or Metastatic Non-small Cell Lung Cancer; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Squamous Cell Carcinoma of Head and Neck … | Dec 2026 |
| ArriVent BioPharma | Firmonertinib Epidermal growth factor receptor erbB1 inhibitor | EGFR | Phase 3 | Metastatic Non-Small Cell Lung Cancer; Non-Small-Cell Lung Cancer; Non-Small Cell Lung Cancer (NSCLC) | Dec 2026 |
| Jiangsu Hansoh Pharmaceutical | HS-10504 EGFR C797S mutation-targeting tyrosine kinase inhibitor | EGFR | Phase 3 | Advanced or Metastatic NSCLC; Locally Advanced or Metastatic NSCLC | Dec 2026 |
| Johnson & Johnson (Janssen) | Lazertinib Epidermal growth factor receptor erbB1 inhibitor | EGFR | Phase 3 | Advanced or Metastatic Non-small Cell Lung Cancer; Carcinoma, Non-Small-Cell Lung; Carcinoma, Non-small-Cell Lung; Non-Small-Cell Lung Cancer … | Dec 2026 |
| Jiangsu Hansoh Pharmaceutical | Aumolertinib Epidermal growth factor receptor erbB1 inhibitor | EGFR | Phase 3 | Non-small Cell Lung Cancer; Non Small Cell Lung Cancer; Non-Small Cell Lung Cancer; Lung Cancer … | Jan 2027 |
| Pfizer | Cetuximab Epidermal growth factor receptor erbB1 inhibitor | EGFR | Phase 3 | Neoplasms; Metastatic Colorectal Cancer | Jan 2027 |
| National Cancer Institute (NCI) | Erlotinib Hydrochloride Epidermal growth factor receptor erbB1 inhibitor | EGFR | Phase 3 | Lung Non-Squamous Non-Small Cell Carcinoma; Recurrent Lung Non-Small Cell Carcinoma; Hereditary Leiomyomatosis and Renal Cell Carcinoma; Adult Solid Neoplasm … | Feb 2027 |
| Betta Pharmaceuticals | Befotertinib EGFR tyrosine kinase inhibitor | EGFR | Phase 3 | Non-Small Cell Lung Cancer; NSCLC; DDI (Drug-Drug Interaction); Non-small Cell Lung Cancer (NSCLC) … | Apr 2027 |
| Taiho Oncology | Cln-081 (TAS6417) Epidermal growth factor receptor erbB1 inhibitor | EGFR | Phase 3 | Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation; Lung Cancer; Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations | May 2027 |
| Fudan University | Nimotuzumab Epidermal growth factor receptor erbB1 inhibitor | EGFR | Phase 3 | Nasopharyngeal Carcinoma; Head and Neck Squamous Cell Carcinoma | May 2027 |
| Rakuten Medical | ASP-1929 Photoimmunotherapy (PIT) Anti-EGFR photoimmunotherapy agent | EGFR | Phase 3 | Head and Neck Cancer; Recurrent Head and Neck Squamous Cell Carcinoma | Jun 2027 |
| Sunshine Lake Pharma | Larotinib EGFR tyrosine kinase inhibitor | EGFR | Phase 3 | Esophageal Cancer | Aug 2027 |
| Genmab | Petosemtamab (MCLA-158) bispecific antibody targeting EGFR and LGR5 | EGFR, CEACAM5, LGR5 | Phase 3 | Head and Neck Squamous Cell Carcinoma; Colorectal Cancer; Left-sided Colorectal Cancer; Advanced/Metastatic Solid Tumors | Jan 2028 |
| Nanjing Sanhome Pharmaceutical | SH-1028 tablets EGFR tyrosine kinase inhibitor | EGFR | Phase 3 | Non-small Cell Lung Cancer | Feb 2028 |
| Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Neratinib Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor | EGFR, ERBB2, ERBB4 | Phase 3 | Early-stage Breast Cancer | Feb 2028 |
| Amgen | Panitumumab Epidermal growth factor receptor erbB1 inhibitor | EGFR | Phase 3 | Metastatic Colorectal Cancer; Advanced Solid Tumors; Colorectal Cancer Stage IV; Colorectal Neoplasms … | Jul 2028 |
| Region Skane | Afatinib Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor | EGFR, ERBB2, ERBB4 | Phase 3 | Non-Small Cell Lung Cancer | Sep 2028 |
| Rakuten Medical | Cetuximab Sarotalocan (ASP-1929) Epidermal growth factor receptor erbB1 binding agent | EGFR | Phase 3 | Recurrent Head and Neck Squamous Cell Carcinoma | Sep 2028 |
| Region Skane | Dacomitinib Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor | EGFR, ERBB2, ERBB4 | Phase 3 | Non-Small Cell Lung Cancer | Sep 2028 |
| Allist Pharmaceuticals | Furmonertinib Mesilate Tablets EGFR tyrosine kinase inhibitor | EGFR | Phase 3 | NSCLC Patients With Brain Metastasis | Mar 2029 |
| Merck & Co. (MSD) | Cetuximab Epidermal growth factor receptor erbB1 inhibitor | EGFR | Phase 3 | Colon Adenocarcinoma; Lung Neoplasm Malignant | Mar 2029 |
| Taizhou Mabtech Pharmaceutical | Enlituo® EGFR inhibitor monoclonal antibody | EGFR | Phase 3 | Colorectal Cancer; Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M) | Oct 2029 |
| Allist Pharmaceuticals | Alflutinib Mesylate (AST2818) EGFR tyrosine kinase inhibitor | EGFR | Phase 3 | Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non-small Cell Lung Cancer | – |
| Takeda | Mobocertinib Epidermal growth factor receptor erbB1 inhibitor | EGFR | Phase 3 | Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC); Non-Small Cell Lung Cancer; Carcinoma, Non-Small-Cell Lung | – |
| Avistone Biotechnology | PLB1004 EGFR inhibitor | EGFR | Phase 2 | Non-Small-Cell Lung Cancer; NSCLC (Non-small Cell Lung Cancer); Non-Small Cell Lung Cancer | Nov 2026 |
| Fundación GECP | Brigatinib ALK tyrosine kinase receptor inhibitor; Epidermal growth factor receptor erbB1 inhibitor | ALK, EGFR | Phase 2 | Lung Cancer | Nov 2026 |
| Hansoh BioMedical R&D Company | HS-20117-2 Injection EGFR-MET bispecific antibody | EGFR, MET | Phase 2 | Non-Squamous Non-Small Cell Lung Cancer; Solid Tumors; Advanced Solid Tumors | Dec 2026 |
| Peking University Cancer Hospital & Institute | Icotinib Epidermal growth factor receptor erbB1 inhibitor | EGFR | Phase 2 | Non-Small Cell Lung Cancer | Dec 2026 |
| Shanghai Pulmonary Hospital, Shanghai, China | Limertinib 3rd generation EGFR tyrosine kinase inhibitor (TKI) | EGFR | Phase 2 | EGFR-mutant Non-small Cell Lung Cancer | Dec 2026 |
| National University Hospital, Singapore | Afatinib Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor | EGFR, ERBB2, ERBB4 | Phase 2 | NSCLC | Dec 2026 |
| Yale University | Afatinib Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor | EGFR, ERBB2, ERBB4 | Phase 2 | HER2/Neu+ Uterine Serous Carcinoma | Dec 2026 |
| University Medical Center Groningen | Cetuximab-800CW EGFR inhibitor conjugated with NIR fluorophore (800CW) | EGFR | Phase 2 | Barrett's Esophagus Without Dysplasia | Dec 2026 |
| Ruth O'Regan | Neratinib Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor | EGFR, ERBB2, ERBB4 | Phase 2 | Breast Cancer | Dec 2026 |
| Hunan Province Tumor Hospital | Erlotinib Epidermal growth factor receptor erbB1 inhibitor | EGFR | Phase 2 | Non Small Cell Lung Cancer | Dec 2026 |
| Hunan Province Tumor Hospital | Gefitinib Epidermal growth factor receptor erbB1 inhibitor | EGFR | Phase 2 | Non Small Cell Lung Cancer | Dec 2026 |
| Xuekui Liu | Becotatug Vedotin EGFR-directed antibody-drug conjugate with MMAE payload | EGFR | Phase 2 | Head and Neck Squamous Cell Carcinoma, HNSCC | Dec 2026 |
| National Cancer Institute (NCI) | Afatinib Dimaleate Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor | EGFR, ERBB2, ERBB4 | Phase 2 | Advanced Lymphoma | Jan 2027 |
| Zhejiang University | Nimotuzumab Epidermal growth factor receptor erbB1 inhibitor | EGFR | Phase 2 | Metastatic Pancreatic Carcinoma; Borderline Resectable Pancreatic Adenocarcinoma | Feb 2027 |
| H. Lee Moffitt Cancer Center and Research Institute | Afatinib Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor | EGFR, ERBB2, ERBB4 | Phase 2 | Squamous Cell Carcinoma | Feb 2027 |
| National Cancer Institute (NCI) | Neratinib Maleate Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor | EGFR, ERBB2, ERBB4 | Phase 2 | Malignant Female Reproductive System Neoplasm; Metastatic Malignant Solid Neoplasm | Feb 2027 |
| National Cancer Centre, Singapore | Dacomitinib Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor | EGFR, ERBB2, ERBB4 | Phase 2 | NSCLC Stage IIIB; Advanced Solid Tumours | Apr 2027 |
| City of Hope Medical Center | Lapatinib ditosylate Receptor protein-tyrosine kinase erbB-2 inhibitor; Epidermal growth factor receptor erbB1 inhibitor | ERBB2, EGFR | Phase 2 | Breast Neoplasms | Apr 2027 |
| Hunan Province Tumor Hospital | Sunvozertinib EGFR inhibitor | EGFR | Phase 2 | Non-Small Cell Lung Cancer; Non-small Cell Lung Cancer | Apr 2027 |
| Shanghai Chest Hospital | Dacomitinib Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor | EGFR, ERBB2, ERBB4 | Phase 2 | Non-small Cell Lung Cancer Metastatic; Non-Small Cell Lung Cancer (NSCLC) | May 2027 |
| BeBetter Med | BEBT-109 EGFR exon 20 insertion inhibitor | EGFR | Phase 2 | Non-Small Cell Lung Cancer; Non Small Cell Lung Cancer | Jun 2027 |
| Shanghai Junshi Bioscience Co., Ltd. | JS212 for Injection Bispecific antibody-drug conjugate targeting EGFR and HER3 with topoisomerase I inhibitor | EGFR, HER3 | Phase 2 | Advanced Esophageal Squamous Cell Carcinoma; Advanced Malignant Solid Tumors; Advanced Lung Cancer; Metastatic Colorectal Cancer … | Jun 2027 |
| Wayshine Biopharm | WSD0922-FU EGFR-TKI (third-generation) | EGFR | Phase 2 | Non Small Cell Lung Cancer; EGFR Mutation Positive Advanced Non-Small Cell Lung Cancer; Non Small Cell Lung Cancer (NSCLC) | Jun 2027 |
| Second Affiliated Hospital, Zhejiang University, School of Medicine | befotertinib third-generation EGFR tyrosine kinase inhibitor targeting non-classical EGFR mutations | EGFR | Phase 2 | NSCLC (Non-small Cell Lung Cancer) | Jun 2027 |
| Novartis | Nazartinib Epidermal growth factor receptor erbB1 inhibitor; Epidermal growth factor receptor inhibitor | EGFR | Phase 2 | Advanced Solid Tumors Which Are cMET-dependent; EGFR-mutant Non-small Cell Lung Cancer | Jul 2027 |
| University Health Network, Toronto | Neratinib Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor | EGFR, ERBB2, ERBB4 | Phase 2 | Breast Cancer | Jul 2027 |
| Fudan University | Vebrekotuzumab EGFR-targeting antibody-drug conjugate (ADC) | EGFR | Phase 2 | Esophageal Squamous Cell Carcinoma | Aug 2027 |
| Fudan University | EGFR-TKI EGFR tyrosine kinase inhibitor (3rd generation) | EGFR | Phase 2 | Brain Metastases | Aug 2027 |
| University of Texas Southwestern Medical Center | Afatinib Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor | EGFR, ERBB2, ERBB4 | Phase 2 | Advanced Squamous Non Small Cell Lung Cancer | Sep 2027 |
| University of Rochester | Neratinib Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor | EGFR, ERBB2, ERBB4 | Phase 2 | Breast Cancer | Sep 2027 |
| National Taiwan University Hospital | Afatinib Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor | EGFR, ERBB2, ERBB4 | Phase 2 | NSCLC Stage IV | Oct 2027 |
| Bicara Therapeutics | Ficerafusp alfa (BCA101) Bispecific antibody targeting EGFR and TGF-β | EGFR, TGFB1 | Phase 2 | Metastatic Head and Neck Squamous Cell Carcinoma; Head and Neck Squamous Cell Carcinoma; Head and Neck Squamous Cell Carcinoma (HNSCC); Squamous Cell Carcinoma of Head and Neck (SCCHN) | Oct 2027 |
| Massachusetts General Hospital | Afatinib Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor | EGFR, ERBB2, ERBB4 | Phase 2 | Lung Cancer; Advanced Solid Tumor | Dec 2027 |
| Massachusetts General Hospital | Erlotinib Epidermal growth factor receptor erbB1 inhibitor | EGFR | Phase 2 | Non-small Cell Lung Cancer | Dec 2027 |
| Teligene US | Sutetinib Maleate Capsule EGFR tyrosine kinase inhibitor targeting uncommon mutations (L861Q, G719X, S768I) | EGFR | Phase 2 | Non-small Cell Lung Cancer | Dec 2027 |
| Black Diamond Therapeutics | silevertinib (BDTX-1535) 4th generation irreversible EGFR inhibitor targeting classical and non-classical driver an | EGFR | Phase 2 | Glioblastoma (GBM); Non-Small Cell Lung Cancer | Dec 2027 |
| Sun Yat-sen University | Befotertinib Irreversible, third-generation, mutant-selective EGFR inhibitor | EGFR | Phase 2 | Non-small Cell Lung Cancer Metastatic | Dec 2027 |
| Sun Yat-sen University | Icotinib Epidermal growth factor receptor erbB1 inhibitor | EGFR | Phase 2 | Non-small Cell Lung Cancer Metastatic | Dec 2027 |
| Shanghai EpimAb Biotherapeutics | Bafisontamab (EMB-01) Hepatocyte growth factor receptor inhibitor; Epidermal growth factor receptor erbB1 inhibitor | MET, EGFR | Phase 2 | Metastatic Colorectal Cancer; Unresectable/Metastatic Colorectal Cancer | Dec 2027 |
| Shanghai Henlius Biotech | Pimurutamab (HLX07) Epidermal growth factor receptor erbB1 inhibitor | EGFR | Phase 2 | Carcinoma of Head and/or Neck; Advanced or Metastatic Squamous Non-Small Cell Lung Cancer; Rectal Cancer | Dec 2027 |
| Shandong Public Health Clinical Center | Afatinib Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor | EGFR, ERBB2, ERBB4 | Phase 2 | Carcinoma, Non-Small-Cell Lung | Dec 2027 |
| Fujian Cancer Hospital | MRG003 anti-EGFR monoclonal antibody | EGFR | Phase 2 | Nasopharyngeal Carcinoma | Dec 2027 |
| Centre Leon Berard | Lapatinib Receptor protein-tyrosine kinase erbB-2 inhibitor; Epidermal growth factor receptor erbB1 inhibitor | ERBB2, EGFR | Phase 2 | Malignant Solid Neoplasms | Jan 2028 |
| David Reardon, MD | Neratinib Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor | EGFR, ERBB2, ERBB4 | Phase 2 | Glioblastoma | Feb 2028 |
| University Health Network, Toronto | Brigatinib ALK tyrosine kinase receptor inhibitor; Epidermal growth factor receptor erbB1 inhibitor | ALK, EGFR | Phase 2 | Pancreatic Ductal Carcinoma | Feb 2028 |
| Memorial Sloan Kettering Cancer Center | Gefitinib Epidermal growth factor receptor erbB1 inhibitor | EGFR | Phase 2 | Osteosarcoma | Mar 2028 |
| H. Lee Moffitt Cancer Center and Research Institute | Neratinib Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor | EGFR, ERBB2, ERBB4 | Phase 2 | GastroEsophageal Cancer | Mar 2028 |
| Fudan University | Becotatug Vedotin (MRG003) EGFR-targeted antibody-drug conjugate | EGFR | Phase 2 | Hepato Cellular Carcinoma (HCC); Metastatic Colorectal Cancer; Thyroid Cancer; Penile Cancer | Apr 2028 |
| Ji Dongmei | MRG003 anti-EGFR antibody-drug conjugate | EGFR | Phase 2 | Salivary Gland Carcinomas | May 2028 |
| Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Cetuximab-beta Anti-EGFR antibody; blocks EGFR-related cancer cell growth signals | EGFR | Phase 2 | Metastatic Colorectal Cancer (CRC) | Oct 2028 |
| Intergroupe Francophone de Cancerologie Thoracique | Brigatinib ALK tyrosine kinase receptor inhibitor; Epidermal growth factor receptor erbB1 inhibitor | ALK, EGFR | Phase 2 | Non Small Cell Lung Cancer | Oct 2028 |
| Peng Zhang | Befotertinib EGFR tyrosine kinase inhibitor | EGFR | Phase 2 | EGFR | Dec 2028 |
| Shanghai Chest Hospital | Osimertinib-based adaptive treatment Third-generation EGFR tyrosine kinase inhibitor, selective for EGFR mutations | EGFR | Phase 2 | Locally Advanced or Metastatic EGFRm Non-small Cell Lung Cancer (NSCLC) | Jan 2029 |
| Nanfang Hospital, Southern Medical University | EGFR-TKIs Combined with PD-1 Monoclonal Antibody EGFR tyrosine kinase inhibitor combined with PD-1 inhibitor | EGFR, PDCD1 | Phase 2 | Lung Cancer Non-Small Cell Cancer (NSCLC) | Mar 2029 |
| Groupe Oncologie Radiotherapie Tete et Cou | MRG003 EGFR-targeting antibody-drug conjugate | EGFR | Phase 2 | Locally Advanced Head and Neck Squamous Cell Carcinoma | Jun 2029 |
| Fudan University | Neratinib Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor | EGFR, ERBB2, ERBB4 | Phase 2 | Breast Cancer With Brain Metastasis | Aug 2029 |
| Scott R. Plotkin, MD, PhD | Brigatinib ALK tyrosine kinase receptor inhibitor; Epidermal growth factor receptor erbB1 inhibitor | ALK, EGFR | Phase 2 | Neurofibromatosis Type 2 | Dec 2029 |
| Scott R. Plotkin, MD, PhD | Neratinib Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor | EGFR, ERBB2, ERBB4 | Phase 2 | Neurofibromatosis Type 2 | Dec 2029 |
| Spanish Breast Cancer Research Group | Neratinib Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor | EGFR, ERBB2, ERBB4 | Phase 2 | Early-stage Breast Cancer | Jan 2030 |
| Vanderbilt-Ingram Cancer Center | Neratinib Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor | EGFR, ERBB2, ERBB4 | Phase 2 | Anatomic Stage I Breast Cancer | Apr 2030 |
| Groupe Francais De Pneumo-Cancerologie | Brigatinib ALK tyrosine kinase receptor inhibitor; Epidermal growth factor receptor erbB1 inhibitor | ALK, EGFR | Phase 2 | NSCLC | Oct 2030 |
| Guangdong Association of Clinical Trials | icotinib Epidermal growth factor receptor erbB1 inhibitor | EGFR | Phase 2 | MRD | Oct 2030 |
| Dartmouth-Hitchcock Medical Center | Neratinib Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor | EGFR, ERBB2, ERBB4 | Phase 2 | Advanced Breast Cancer | Oct 2030 |
| Dizal Pharmaceuticals | DZD9008 EGFR inhibitor | EGFR | Phase 2 | Non-small Cell Lung Cancer | – |
| Baylor Breast Care Center | Lapatinib Receptor protein-tyrosine kinase erbB-2 inhibitor; Epidermal growth factor receptor erbB1 inhibitor | ERBB2, EGFR | Phase 2 | Breast Cancer | – |
| AstraZeneca | Necitumumab Epidermal growth factor receptor erbB1 inhibitor | EGFR | Phase 2 | Non-Small Cell Lung Cancer; Metastatic Lung Non-Small Cell Carcinoma | – |
| XIANG YANQUN | Nituzumab Anti-EGFR monoclonal antibody | EGFR | Phase 2 | Nasopharyngeal Cancer | – |
| UNICANCER | Sapitinib (AZD8931) Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor tyrosine-protein kinase erbB-3 inhibitor; Epidermal growth factor receptor erbB1 inhibitor | ERBB2, ERBB3, EGFR | Phase 2 | Metastatic Breast Cancer | – |
| Stanford University | Panitumumab-IRDye800 anti-EGFR monoclonal antibody conjugated to IRDye800CW near-infrared fluorescent dye for i | EGFR | Phase 1 | Malignant Brain Neoplasm; Lung Carcinoma; Brain Tumor | Nov 2026 |
| Roswell Park Cancer Institute | Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine (CIMAvax) EGF-directed cancer vaccine | EGFR | Phase 1 | Advanced Head and Neck Squamous Cell Carcinoma | Nov 2026 |
| University of Saskatchewan | 89Zr-DFO-nimotuzumab EGFR-targeting monoclonal antibody conjugated to zirconium-89 for PET imaging | EGFR | Phase 1 | Lung Cancer | Dec 2026 |
| Jiangsu Aosaikang Pharmaceutical | ASK120067 (Limertinib) EGFR tyrosine kinase inhibitor | EGFR | Phase 1 | Advanced Solid Tumor | Dec 2026 |
| Jeeyun Lee | Afatinib Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor | EGFR, ERBB2, ERBB4 | Phase 1 | Stomach Neoplasm | Dec 2026 |
| Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical | TQB2922 for injection anti-EGFR/c-Met bispecific antibody | EGFR, MET | Phase 1 | Advanced Cancer; RAS/BRAF Wild Type Colorectal Cancer | Dec 2026 |
| Phrontline Biopharma | TJ101 EGFR/B7H3-directed antibody-drug conjugate with cleavable linker and novel topoisomerase I | EGFR, B7H3 | Phase 1 | Lung Cancer (NSCLC) | Dec 2026 |
| Acepodia Biotech | ACE2016 Allogeneic gamma delta T (gdT) cell therapy engineered to target EGFR-expressing tumors | EGFR | Phase 1 | Locally Advanced Solid Tumor | Dec 2026 |
| AstraZeneca | FPI-2053 Bispecific antibody targeting EGFR and cMET | EGFR, MET | Phase 1 | Advanced Solid Tumor | Dec 2026 |
| Henan Genuine Biotech | GEN-725 EGFR tyrosine kinase inhibitor | EGFR | Phase 1 | Advanced Solid Tumors; Non-Small Cell Lung Cancer | Dec 2026 |
| Shanghai Henlius Biotech | HLX05 anti-EGFR monoclonal antibody | EGFR | Phase 1 | Cancer; EGFR Overexpression | Dec 2026 |
| AstraZeneca | [111In]-FPI-2107 Imaging agent (indium-111 conjugated to FPI-2053 bispecific antibody targeting EGFR and cM | EGFR, MET | Phase 1 | Advanced Solid Tumor | Dec 2026 |
| AstraZeneca | [225Ac]-FPI-2068 Alpha-emitting radiopharmaceutical (actinium-225) conjugated to bispecific antibody target | EGFR, MET | Phase 1 | Advanced Solid Tumor | Dec 2026 |
| Beijing Biotech | EB-G3B7-NK dual-target CAR-NK cells Dual-targeting CAR-NK cells directed against IL13Rα2, EGFR/EGFRvIII, or B7-H3 (CD276) expr | CD276, MSLN, EGFR, ERBB2, IL13RA2 | Phase 1 | Non-Small Cell Lung Cancer; Breast Cancer (Locally Advanced or Metastatic); Glioblastoma; Advanced Hepatocellular Carcinoma (HCC) … | Feb 2027 |
| Suzhou Zelgen Biopharmaceuticals | Gecacitinib Tyrosine kinase inhibitor targeting EGFR | EGFR | Phase 1 | Healthy; Lymphoma; Non-small Cell Lung Cancer; Cervical Cancer … | Feb 2027 |
| Chia Tai Tianqing Pharmaceutical Group | TQB6411 for Injection EGFR/c-Met dual-targeting antibody-drug conjugate | EGFR, MET | Phase 1 | Esophageal Cancer; Advanced Lung Cancer | Feb 2027 |
| Beijing Biotech | EGFR/HER2 Dual-Target CAR-NK Cells Allogeneic donor-derived NK cells engineered to express dual EGFR/HER2 chimeric antigen re | EGFR, ERBB2 | Phase 1 | Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | Mar 2027 |
| Abbisko Therapeutics | ABSK112 EGFR Exon20 inhibitor | EGFR | Phase 1 | Non-Small Cell Lung Cancer | Mar 2027 |
| Memorial Sloan Kettering Cancer Center | EGFRt/19-28z/4-1BBL CAR T cells CD19-targeting CAR T cell therapy with 28z costimulatory domain and 4-1BB ligand; EGFRt se | CD19, EGFR | Phase 1 | Chronic Lymphocytic Leukemia (CLL) | Mar 2027 |
| Shanghai Henlius Biotech | HLX48 EGFR/c-MET bispecific antibody-drug conjugate | EGFR, MET | Phase 1 | Advanced/Metastatic Solid Tumors | Mar 2027 |
| City of Hope Medical Center | Brigatinib ALK tyrosine kinase receptor inhibitor; Epidermal growth factor receptor erbB1 inhibitor | ALK, EGFR | Phase 1 | Locally Advanced Lung Non-Small Cell Carcinoma | Mar 2027 |
| Hangzhou Zhongmei Huadong Pharmaceutical | HDM2024 Antibody-drug conjugate targeting EGFR and HER3 | EGFR, HER3 | Phase 1 | Advanced Solid Tumors | Apr 2027 |
| Memorial Sloan Kettering Cancer Center | anti-EGFR-bispecific antibody armed activated T-cells (EGFR BATs) anti-EGFR bispecific antibody-armed activated T-cells | EGFR | Phase 1 | Pancreatic Cancer | Apr 2027 |
| National Cancer Institute (NCI) | Lapatinib Receptor protein-tyrosine kinase erbB-2 inhibitor; Epidermal growth factor receptor erbB1 inhibitor | ERBB2, EGFR | Phase 1 | Metastatic Thyroid Gland Carcinoma | May 2027 |
| West China Hospital | Afatinib Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor | EGFR, ERBB2, ERBB4 | Phase 1 | HNSCC; Esophagus Cancer | May 2027 |
| Haisco Pharmaceutical Group | HSK40118 EGFR inhibitor | EGFR | Phase 1 | NSCLC | Jun 2027 |
| Shanghai Henlius Biotech | Cetuximab (HLX42) Epidermal growth factor receptor erbB1 inhibitor | EGFR | Phase 1 | Solid Tumor and NSCLC | Jun 2027 |
| ALX Oncology | ALX2004 anti-EGFR antibody-drug conjugate | EGFR | Phase 1 | NSCLC (Advanced Non-small Cell Lung Cancer) | Jun 2027 |
| Betta Pharmaceuticals | CFT8919 EGFR tyrosine kinase inhibitor | EGFR | Phase 1 | Non-Small Cell Lung Cancer With EGFR Mutation | Jun 2027 |
| Darell Bigner | D2C7-IT EGFR-targeted immunotoxin | EGFR | Phase 1 | Glioma, Malignant; Newly Diagnosed MGMT Unmethylated Glioblastoma; Recurrent Glioblastoma IDH Wildtype | Jun 2027 |
| Dizal Pharmaceuticals | DZD6008 EGFR inhibitor | EGFR | Phase 1 | Non Small Cell Lung Cancer; Nonsmall-cell Lung Cancer; Non-Small Cell Lung Cancer | Jun 2027 |
| Sun Yat-sen University | EGFR Antibody EGFR inhibitor antibody | EGFR | Phase 1 | Nasopharyngeal Cancinoma (NPC) | Jun 2027 |
| Fox Chase Cancer Center | Neratinib Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor | EGFR, ERBB2, ERBB4 | Phase 1 | Gastric Cancer | Jun 2027 |
| Yuhan | YH32364 EGFR-targeting agent | EGFR | Phase 1 | EGFR Overexpression | Jun 2027 |
| HC Biopharma | HC034S EGFR inhibitor monoclonal antibody (cetuximab biosimilar) | EGFR | Phase 1 | Cetuximab | Jun 2027 |
| Innovent Biopharmaceutical Technology (Hangzhou) | IBI3028 Recombinant anti-EGFR and c-Met antibodies dual-payload conjugate | EGFR, MET | Phase 1 | Solid Tumor | Jun 2027 |
| Jonsson Comprehensive Cancer Center | ERAS-801 EGFR inhibitor | EGFR | Phase 1 | Glioblastoma | Jul 2027 |
| UNC Lineberger Comprehensive Cancer Center | Erlotinib Epidermal growth factor receptor erbB1 inhibitor | EGFR | Phase 1 | Pancreatic Adenocarcinoma | Aug 2027 |
| Dana-Farber Cancer Institute | Gefitinib Epidermal growth factor receptor erbB1 inhibitor | EGFR | Phase 1 | Non-Small Cell Lung Cancer | Oct 2027 |
| Memorial Sloan Kettering Cancer Center | Neratinib Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor | EGFR, ERBB2, ERBB4 | Phase 1 | Solid Tumor | Oct 2027 |
| Virginia Commonwealth University | Neratinib Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor | EGFR, ERBB2, ERBB4 | Phase 1 | Advanced Solid Tumor | Oct 2027 |
| BeOne Medicines | BG-C0902 Bispecific anti-EGFR and anti-MET antibody-drug conjugate with topoisomerase 1 inhibitor p | EGFR, MET | Phase 1 | Solid Tumors | Nov 2027 |
| Pierre Fabre Medicament | STX-241 Mutant-selective CNS-penetrant fourth generation EGFR tyrosine kinase inhibitor | EGFR | Phase 1 | Non-small Cell Lung Cancer (NSCLC) | Nov 2027 |
| M.D. Anderson Cancer Center | Cytokine-treated Veto Cells CAR-T/CAR-NK cell therapy targeting IL-13 receptor alpha-1 and EGFvIII on glioblastoma cel | IL13RA1, EGFR, IL21, TGFBR2, NR3C1, TROP2 | Phase 1 | Acute Lymphoblastic Leukemia; Acute Myeloid Leukemia; Phase 1; Colorectal Cancer | Dec 2027 |
| University of Virginia | EGFR FPBMC CD3 x EGFR bispecific antibody-armed fresh peripheral blood mononuclear cells | CD3, EGFR | Phase 1 | Pancreas Cancer | Dec 2027 |
| Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical | TQB6411 injection EGFR/c-Met dual-targeting antibody-drug conjugate (ADC) | EGFR, MET | Phase 1 | Advanced Malignant Tumors | Dec 2027 |
| Mustafa Khasraw, MBChB, MD, FRCP, FRACP | hEGFRvIII-CD3 (BRiTE) Bispecific T cell engager with one arm binding CD3 on T cells and the opposing arm binding | EGFR, CD3E | Phase 1 | Newly Diagnosed Glioblastoma | Dec 2027 |
| Henan Genuine Biotech | Dositinib mesylate tablets (90-1408) EGFR inhibitor | EGFR | Phase 1 | Non-Small Cell Lung Cancer | Dec 2027 |
| Vanderbilt-Ingram Cancer Center | Panitumumab-IRDye800 EGFR-targeted monoclonal antibody conjugated to fluorescent IRDye800 dye | EGFR | Phase 1 | Head and Neck Squamous Cell Carcinoma; HNSCC; HNSCC,Larynx, Pharynx and Oral Cavity | Dec 2027 |
| Yuhan | YH42946 Dual EGFR exon 20 insertion and HER2 inhibitor | EGFR, ERBB2 | Phase 1 | NSCLC (Non-small Cell Lung Cancer) | Mar 2028 |
| Alpha Biopharma (Jiangsu) | Azd-3759 Epidermal growth factor receptor erbB1 inhibitor | EGFR | Phase 1 | Patients With Advanced Non-small Cell Lung Cancer With Meningeal Progression After Osimertinib Treatment | Apr 2028 |
| Betta Pharmaceuticals | MCLA-129 bispecific antibody targeting EGFR and cMET | EGFR, MET | Phase 1 | Solid Tumor; Solid Advanced Tumor | Apr 2028 |
| M.D. Anderson Cancer Center | Brigatinib ALK tyrosine kinase receptor inhibitor; Epidermal growth factor receptor erbB1 inhibitor | ALK, EGFR | Phase 1 | Advanced Lung Carcinoma; Brain Metastasis | Jun 2028 |
| Jiangsu Alphamab Biopharmaceuticals | Furmonertinib Mesylate EGFR tyrosine kinase inhibitor | EGFR | Phase 1 | Advanced Non-small Cell Lung Cancer | Jun 2028 |
| Changchun GeneScience Pharmaceutical | GenSci139 bispecific antibody drug conjugate targeting EGFR and HER2 | EGFR, HER2 | Phase 1 | Advanced Solid Tumors | Jul 2028 |
| Suzhou Junjing BioSciences | JS111 capsules (AP-L1898) EGFR inhibitor | EGFR | Phase 1 | NSCLC | Jul 2028 |
| R-Pharm | Panitumumab (RPH-030) Epidermal growth factor receptor erbB1 inhibitor | EGFR | Phase 1 | Metastatic Colorectal Cancer | Aug 2028 |
| Bayer | BAY2927088 (sevabertinib) Tyrosine kinase inhibitor targeting mutated EGFR and HER2 | EGFR, HER2 | Phase 1 | Advanced Non-small Cell Lung Cancer | Dec 2028 |
| Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau | Afatinib Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor | EGFR, ERBB2, ERBB4 | Phase 1 | Fanconi Anemia | Dec 2028 |
| Tongji University | HJ-004-02 EGFR tyrosine kinase inhibitor | EGFR | Phase 1 | NSCLC (Advanced Non-small Cell Lung Cancer) | Dec 2028 |
| Voronoi | VRN110755 Selective oral EGFR inhibitor targeting activating EGFR mutations and resistance mutations | EGFR | Phase 1 | EGFR-Mutant Non-Small Cell Lung Cancer | Jan 2029 |
| BlossomHill Therapeutics | BH-30643 Dual EGFR/HER2 inhibitor | EGFR, HER2 | Phase 1 | NSCLC (Advanced Non-small Cell Lung Cancer) | Jan 2029 |
| NEOK Bio | NEOK002 EGFR and MUC1-targeting bispecific antibody-drug conjugate (ADC) | EGFR, MUC1 | Phase 1 | Locally Advanced (Unresectable) or Metastatic Solid Tumors | Feb 2029 |
| A2 Biotherapeutics | A2B395 Allogeneic logic-gated CAR T cells targeting EGFR with HLA-A*02 loss as kill-switch | EGFR | Phase 1 | Solid Tumor, Adult | Mar 2029 |
| Vanderbilt-Ingram Cancer Center | [18F]NOTA-ABY030 Radiolabeled anti-EGFR affibody for PET imaging | EGFR | Phase 1 | SCC - Squamous Cell Carcinoma | Apr 2029 |
| EpiBiologics | EPI-326 tissue-selective bispecific antibody targeting EGFR | EGFR | Phase 1 | Epidermal Growth Factor | Jul 2029 |
| Vir Biotechnology | VIR-5525 EGFR-targeting immunotherapy | EGFR | Phase 1 | Solid Tumor Malignancies | Aug 2029 |
| Pierre Fabre Medicament | STX-721/PFL-721 Exon 20 insertion-selective tyrosine kinase inhibitor | EGFR, HER2 | Phase 1 | Non-Small Cell Lung Cancer | Dec 2029 |
| Shanghai Chia Tai Tianqing Pharmaceutical Technology Development | TQB2922 injection Bispecific antibody against EGFR and c-Met | EGFR, MET | Phase 1 | Advanced Cancers | Dec 2029 |
| Princess Maxima Center for Pediatric Oncology | Brigatinib ALK tyrosine kinase receptor inhibitor; Epidermal growth factor receptor erbB1 inhibitor | ALK, EGFR | Phase 1 | Anaplastic Large Cell Lymphoma, ALK-Positive | Dec 2033 |
| Seattle Children's Hospital | second generation 4-1BBζ EGFR806-EGFRt Dual-targeting CAR-T cell therapy against EGFR and CD19 with 4-1BB costimulation | EGFR, CD19 | Phase 1 | Pediatric Solid Tumor | Jun 2040 |
| China Medical University Hospital | Afatinib Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor | EGFR, ERBB2, ERBB4 | Phase 1 | Non-small Cell Lung Cancer | – |
| DEKA Biosciences | DK210 (EGFR) EGFR-targeted therapy | EGFR | Phase 1 | Cancer | – |
| China Medical University Hospital | Erlotinib Epidermal growth factor receptor erbB1 inhibitor | EGFR | Phase 1 | Non-small Cell Lung Cancer | – |
| China Medical University Hospital | Gefitinib Epidermal growth factor receptor erbB1 inhibitor | EGFR | Phase 1 | Non-small Cell Lung Cancer | – |
| Janux Therapeutics | JANX008 EGFR-targeting therapy | EGFR | Phase 1 | Non-Small Cell Lung Cancer | – |
| J Ints Bio | JIN-A02 4th generation EGFR tyrosine kinase inhibitor | EGFR | Phase 1 | EGFR Mutant Advanced Non-small Cell Lung Cancer | – |
| Merus | MCLA-129 bispecific IgG1 antibody targeting EGFR and c-MET receptor tyrosine kinases | EGFR, MET | Phase 1 | Non-Small Cell Lung Cancer Metastatic | – |
| Nalo Therapeutics | NX-019 EGFR inhibitor | EGFR | Phase 1 | EGFR Mutation-Related Tumors | – |
| Ascentage Pharma Group | Osimertinib Mesylate (AZD9291) Epidermal growth factor receptor erbB1 inhibitor | EGFR | Phase 1 | EGFR Positive Non-small Cell Lung Cancer | – |
| Chia Tai Tianqing Pharmaceutical Group | TQB3002 EGFR tyrosine kinase inhibitor | EGFR | Phase 1 | Advanced Cancer | – |
Non-Small Cell Lung Cancer (40) Non-small Cell Lung Cancer (29) Non Small Cell Lung Cancer (23) Carcinoma, Non-Small-Cell Lung (22) Breast Cancer (21) NSCLC (13) Lung Cancer (12) Head and Neck Squamous Cell Carcinoma (11) Non-Small-Cell Lung Cancer (8) Advanced Solid Tumor (8) Metastatic Lung Non-Small Cell Carcinoma (7) Metastatic Colorectal Cancer (7)
small molecule (117), mixed (41), antibody (17), protein or peptide (4), other (3)
Fudan University (6) AstraZeneca (5) National Cancer Institute (NCI) (4) Sun Yat-sen University (4) Shanghai Henlius Biotech (4) Memorial Sloan Kettering Cancer Center (4) Allist Pharmaceuticals (3) Hunan Province Tumor Hospital (3) China Medical University Hospital (3) Dizal Pharmaceuticals (3) Vanderbilt-Ingram Cancer Center (3) Betta Pharmaceuticals (3) Jiangsu Hansoh Pharmaceutical (2) Johnson & Johnson (Janssen) (2) Massachusetts General Hospital (2) Shanghai Chest Hospital (2) Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical (2) H. Lee Moffitt Cancer Center and Research Institute (2) University Health Network, Toronto (2) Shanghai JMT-Bio (2)
ERBB2 (42) ERBB4 (32) MET (15) ALK (8) HER2 (4) HER3 (3) CD19 (2) ERBB3 (1) CEACAM5 (1) LGR5 (1) B7H3 (1) MUC1 (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.